TEN, ADLS, PennyOmega.com Watch List ! for Tuesday September 1st, 2009, Tenneco Inc. and Advanced Life Sciences Holdings Inc, ADLS.OB

Source: http://pennyomega.com/?p=863
Posted on Monday, August 31st, 2009 | In Stocks to Watch

Contributed by: Penny Omega (http://pennyomega.com) -

TEN, Tenneco Inc.

ADLS, Advanced Life Sciences Holdings Inc, ADLS.OB

PennyOmega.com Watch List!

PennyOmega.com Watch List ! for Tuesday September 1st, 2009

Our Picks at PennyOmega.com for Tuesday September 1st, 2009 are:

**************************************************************

TEN, Tenneco Inc.

TEN has grown to become one of the world’s leading designers, manufacturers and distributors of emission control and ride control products and systems for the automotive original equipment market and the aftermarket. The company is well-balanced across product lines, markets served and geographic regions.

Using a combination of leading-edge technology, manufacturing expertise and dedication to customer service, TEN has increased revenues to $5.9 billion annually and penetrated new markets to solidify its leadership in the global automotive supply industry. TEN is well positioned to capture significant revenue growth going forward as the result of stricter light and commercial vehicle emission regulations being implemented in most markets worldwide over the next five years.

**Standard & Poor’s Ratings Services raised its outlook to “Positive” from “Negative” and affirmed its “B-” rating on TEN debt, because of its relatively strong second-quarter results and improving prospects.

More abut TEN at www.tenneco.com

**************************************************************

ADLS, Advanced Life Sciences Holdings Inc, ADLS.OB

ADLS is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases.

ADLS is developing Restanza as a broad spectrum medical countermeasure for biodefense. The FDA has designated Restanza as an orphan drug for the post-exposure prophylactic treatment of inhalation anthrax, but the FDA has not yet approved the drug for marketing in this or any other indication.

In addition to its development in anthrax, Restanza is also being developed to combat other high priority bioterror agents such as Fransicella tularensis (tularemia), Yersinia pestis (plague) and Burkholderia pseudomallei (melioidosis) under a two year, $3.8 million contract with the Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense.

**ADLS today announced positive results from an animal study involving its novel, once-a-day, oral antibiotic Restanza(TM) (cethromycin) that was conducted to measure Restanza’s therapeutic efficacy in treating inhalation anthrax after symptoms of infection had developed.

The results of this pivotal study complement previously reported efficacy results from two non-human primate studies showing that Restanza is highly effective in protecting animals from death after being infected with inhalation anthrax (post-exposure prophylaxis before the onset of symptoms). In those studies, Restanza achieved a 100% survival rate against an inhaled lethal dose of anthrax when treatment was initiated within 24 hours of challenge compared to 0% survival rate in placebo-treated animals.

More about ADLS at www.advancedlifesciences.com

**************************************************************

TEN and ADLS are on PennyOmega.com’s RADAR! Do your Homework, and like always BE READY for the Action!!!

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more) . Rule 17B requires disclosure of payment for investor relations.